Saving Development Time with Single Vendor Approach

Watch the webinar “Saving Development Time with Single Vendor Approach” to learn how using a single vendor will save you time and money.

Hear from a client, who recently worked with Thermo Fisher Patheon on the Integrated Offering Quick to Care™️ program, who will offer insight and describe what lessons were learned.
Learn from the program manager that built a strong partnership focusing on the importance of speed to market and cost savings for the client.
Review the Integrated Offering and how it is defined for the client, with the focus on simplicity, time savings, reduced risk and proven experience.

Related Sites

Additional Resources

Saving development time and economizing distribution with a single-vendor approach

Process Characterization: Ready for the FDA/EU ICH guidelines

Advance your discovery from molecule to medicine

Four Ways to Accelerate Downstream Development

Streamlining small molecule API development and regulatory compliance

Rx softgel solutions: Find the right dosage form to suit your molecule

Small molecule API solution: Taking a big picture approach

The 5 pitfalls of API development

Quick to Care™️ program

Growing Your Biopharma: Ten Questions You're Likely to Face From Investors—And How to Respond to Them

There May Be Dragons: Mapping 7 New & Emerging Pharma Development Risks

5,000L single-use bioreactors: The next generation in biologics manufacturing

A Tale of Two CDMOs: Which Choice Will Your Biopharma Make?

CDMO Timebombs: Five Ways the Wrong Partner Can Lead to Trouble Down the Road

Simplify Your Supply Chain in the Race to Phase 1

Analytical Considerations For Biopharmaceuticals During Commercialization

Small Pharma, Big Opportunity Infographic

Benefits of 5KL Bioreactor When Outsourcing Late-phase Biologics Drug Substance Manufacturing

Practical Implementation of Innovative and Scalable Technologies to Accelerate Biologics Development and Commercialization: A CDMO Perspective

Saving Development Time with Single Vendor Approach

Leveraging Infrastructure Investments and Innovation to Accelerate Biologics Development

Conventional vs. Unconventional Spray Drying Strategies: Development to Commercialization

Accelerating Cell Culture Development through Practical Application of Innovation Technologies

Leveraging Innovative Technologies, Best Practices and Strategies to Accelerate Biologics Development and Commercialization

Using Quality By Design For Process Development And Scale-Up Of A Novel ALS Drug Product

Quick to Care™: Integrated Drug Development and Clinical Services for New and Emerging Pharma

Quick to Clinic™ for Oral Solid Dose

API (Small Molecule) Overview

Biologics Overview

Quick to Clinic™ Delivers Phase I Clinical Trial Material, Fast

Crystallization and Solid State Chemistry Overview

Infographic: 8 Criteria for a More Successful API Partnership

Critical API Attributes and the Major Impact They Can Have on Drug Product Development

What You Need to Know About Process Characterization and Validation For Biologic Processes

Satisfying Aggressive Timelines With a Simplified Supply Chain for Drug Delivery

Spray Drying Processability of Methacrylic Acid Copolymers in Amorphous Dispersions: A QbD Approach

Choosing the Right CDMO for Late Phase Clinical Trials

Process Characterization: Ready For The FDA?

Kaleido Biosciences Successfully Meets Aggressive IND Filing Date Thanks to Strategic Partnership

Identifying and Solving Scale-up Challenges in the Synthesis and Formulation of Small-Molecule APIs

Biopharma Capabilities Overview

Quick to Clinic for Oral Solid Dose

Meeting Milestones and Patient Needs Through Expedited Delivery of Phase I Materials

The Criticality of API CDMO Selection: Insights from a Client

Cost Savings and Speed: The Untapped Value of a Single-Source Solution

Flow Chemistry: A Scale-Up Solution For Modern API Development & Manufacturing

Pharma Services Overview Brochure

How Well Should You Understand Your Crystallization Process (and Solid-State Properties)?

How Well Should You Understand Your Crystallization Process (and Solid-State Properties)?

Six API Challenges That Could Be Slowing Your Development and How to Avoid Them

In-House Versus Outsource: A Decision-Making Guide

Getting to First-in-Human Clinical Trials: A Make-or-Break Milestone for Small Biopharmas

Accelerate Complex Molecule Development by Optimizing Chemical Synthesis and Formulation

Synthesizing Success: Six Principles for Getting Pharmaceutical Development Right from the Start

Implications of Inaccurate Forecasting on Biologics Drug Substance Manufacturing

Biologics Overview: Flexible Biomanufacturing Solutions

So Many Choices: What’s the Right Biomanufacturing Strategy for Me?

Challenges in the Development of Complex Small-Molecule Drugs

What You Need to Know to Avoid Costly Delays in Your API Scale-Up

Case Study: Curbing the Opioid Epidemic with Pacira Pharmaceuticals

Choosing the Best Biomanufacturing Strategy: The Value of a Multi-Pronged Approach

How Can You Avoid the Fallout From Incompatibility Between Your API and Its Formulation?

Characterizing Drug Substance Properties Early Can Optimize Drug Product Formulation

Is Your In-House Strategy Ready for the Uncertainties of Biologic Drug Development?

Managing Demand Uncertainty in Biologics Production

Anticipating the Formulation Challenges of Complex Molecules

Trends and Challenges in Outsourced Oral Solid Dosage Forms

Top 5 Considerations When Looking to Outsource to a Biomanufacturing Partner

The Right Partner Can Improve Flexibility and Mitigate Risks from Forecast Inaccuracy in Biomanufacturing

Consultants’ Guide to Flexible Biomanufacturing Solutions

Top Five Risks Facing Your Small Biopharma Clients Today

Challenges, Risks, and Strategies for Biologic Substance Manufacturing

Challenges and Solutions in Cytotoxins and HPAPIs

Anticipating the Formulation Challenges of Complex Molecules

Solutions to Today’s Biomanufacturing Challenges

Amorphous Dispersion Drug Formulations: A Modern Simulation-Based Approach

Multiplexing: Managing Risk with Proven, Single-Use Solutions

Early Stage Development for Solid Dose Products

© 2021 Thermo Fisher Scientific Inc. All rights reserved. Cookie Use Privacy Terms of Use Modern Slavery Statement

Cookie Use Privacy Terms of Use Modern Slavery Statement

© 2021 Thermo Fisher Scientific Inc. All rights reserved.